Editorial Article
January 2027 Is the Only Date That Matters in E-Prescribing
A market that grew for twenty years without a deadline has just been given one, and it arrives on 1 January 2027.
On that date, the CMS Interoperability and Prior Authorization final rule — CMS-0057-F, published in January 2024 — requires the impacted payers to have implemented and be maintaining a HL7 FHIR Prior Authorization API. The impacted payers are Medicare Advantage organisations, state Medicaid and CHIP fee-for-service programmes, Medicaid managed care plans, CHIP managed care entities, and Qualified Health Plan issuers on the Federally Facilitated Exchanges. Operational provisions generally begin a year earlier, on 1 January 2026, and compliance dates for the API requirements vary somewhat by payer type.
An API mandate on its own would be a technical footnote. What makes this the most consequential date in e-prescribing is the rule’s second mechanism: it adds a prior-authorisation measure to the Promoting Interoperability performance category of the Merit-based Incentive Payment System for eligible clinicians, and to the Medicare Promoting Interoperability Program for eligible and critical access hospitals. That redirects money at prescriber behaviour. A payer that builds an endpoint and a prescriber who never uses it produces no market; a scored quality measure produces one.
The layer with a deadline behind it
Prior authorisation is already the fastest-growing part of the e-prescribing stack. Pheonix Research models it at USD 290 million in 2025 rising to USD 1,130 million in 2033 — 18.53 per cent a year, against 10.59 per cent for the market as a whole. It is the only layer in the market with a dated legal obligation attached to its growth.
The reason it can grow that fast without inventing a new buyer is that the economics are already proven and already public. Automated authorisation returned a median decision in 18 seconds in 2025 across 83 supported medications, up from 40 in 2024, with a 34 per cent automated approval rate for in-scope drugs. It was live for 45,275 prescribers across 20 health systems, with 52 more health systems scheduled to go live during 2026. Where it ran, the share of requests abandoned by prescribers fell from 22 per cent to 4 per cent, denials for lack of information fell 11 per cent, and appeals fell 17 per cent.
Those last three numbers are the ones that get budget approved. Abandonment, denials and appeals are all costs with an owner, and the owner is a provider organisation that can calculate the return without needing a strategy paper. That is why the deployment queue for 2026 is real rather than aspirational — and why the constraint on this layer is implementation capacity, not demand.
The other 66 per cent is the roadmap
A 34 per cent automated approval rate is a statement about how narrow the cleanly automatable subset still is. Two thirds of in-scope authorisations cannot yet be resolved without a human handling them, and every one of those is a product problem with a name attached: missing clinical documentation, ambiguous criteria, medications whose benefit designs do not map cleanly onto the available clinical data.
This is why the forecast is 18.53 per cent rather than the growth rate of a completed technology. The layer grows because the automatable subset keeps widening, and it slows when it stops. Both the payer endpoint and the prescriber-side workflow have to improve together for the subset to widen, which is precisely what a 2027 API obligation is designed to force.
And then there is 2029
Europe runs a different clock, and it is worth understanding that the two dates do different things. The European Health Data Space Regulation was published in the Official Journal on 5 March 2025 and entered into force on 26 March 2025. The Commission must adopt several key implementing acts by March 2027, and key parts of the Regulation enter into application in March 2029 — including, for primary use, cross-border exchange of Patient Summaries and of ePrescriptions and eDispensations.
The American deadline reprices an existing market. The European date creates a new one. Cross-border ePrescription exchange requires conformance testing, translation, identity resolution across member states and a set of services that do not exist at scale today, in a market that is currently a collection of national systems rather than a continental one. That is why European share of global e-prescribing value rises from 21 per cent to 26 per cent by 2033 while North America’s falls from 62 per cent to 55 — not because Europe overtakes America, but because Europe acquires a market it did not previously have.
What breaks the schedule
Two things, and both are worth monitoring rather than assuming away.
The first is slippage. If prior authorisation grows at 12 per cent instead of 18.53 per cent — the rate you would expect if the compliance date is formally deferred and the MIPS measure proves too weak to move prescriber behaviour — the 2033 market lands at about USD 3,622.0 million rather than USD 4,340.0 million. The direction survives; the magnitude does not.
The second is the European implementing acts, due by March 2027 and a precondition for the March 2029 application date. Any delay there moves the European step-change directly, and unlike the US final rule there is no single compliance date to point at, because the Regulation applies in stages and depends on delegated legislation to make it operational.
There is also a live uncertainty in the controlled-substance channel. The DEA’s Special Registrations for Telemedicine and Limited State Telemedicine Registrations rulemaking, docket DEA-407, was published as a proposed rule on 17 January 2025 and had not been finalised at the time of writing. Until it is, telehealth prescribing of controlled substances operates under a registration framework that does not yet exist — which affects both the compliance layer and the specialty demand that flows through telehealth.
The practical reading
For anyone buying in this market, the 2027 date is the best negotiating position they will get. Payers must expose the endpoint; prescribers will be scored on using it; the vendors who can demonstrate a live, referenceable health-system deployment before the deadline have a claim on the renewal cycle that follows. For anyone selling, the deadline is a window rather than a guarantee — the automatable subset, not the API, is what gets paid.
The prescription itself will keep getting cheaper. It is the decision about whether it happens at all that is about to become the most expensive part of the process.
Figures in this article are drawn from the Global E-Prescribing Market Report 2026–2033, built from Surescripts network disclosure, CMS final rule CMS-0057-F, the European Health Data Space Regulation, the Federal Register and the NHS Business Services Authority. No competitor research is cited.
Frequently Asked Questions
What is CMS-0057-F and what does it require?
The CMS Interoperability and Prior Authorization final rule, published January 2024. It requires Medicare Advantage organisations, state Medicaid and CHIP fee-for-service programmes, Medicaid and CHIP managed care entities and Qualified Health Plan issuers on the Federally Facilitated Exchanges to implement and maintain HL7 FHIR APIs covering patient access, provider access, payer-to-payer exchange and prior authorisation. Operational provisions generally begin 1 January 2026; API development and enhancement requirements have compliance dates generally beginning 1 January 2027, varying by payer type.
How large is the prior-authorisation layer of the e-prescribing market?
USD 290 million in 2025, rising to USD 1,130 million by 2033 at an 18.53 per cent CAGR — the fastest-growing of the six layers Pheonix Research models, and the only one with a dated regulatory obligation behind its growth. Prior authorisation and benefit and price intelligence together move from 39.2 per cent of market value in 2025 to 55.1 per cent in 2033.
What is the European equivalent deadline?
The European Health Data Space Regulation was published in the Official Journal on 5 March 2025 and entered into force on 26 March 2025. The Commission must adopt key implementing acts by March 2027, and from March 2029 the primary-use provisions apply, including cross-border exchange of Patient Summaries and ePrescriptions and eDispensations. The US date reprices an existing market; the European date creates a new one.
What happens if the January 2027 deadline slips?
If prior authorisation grows at 12 per cent rather than 18.53 per cent — consistent with a formal deferral and a weak MIPS measure — the 2033 market lands at about USD 3,622.0 million instead of USD 4,340.0 million. Market direction is unaffected because prescription volume is unchanged; what moves is whether the decision layers get priced or bundled into platform licences.
